Promising cancer combo trial for kids ends early

NCT ID NCT05429502

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 24 times

Summary

This study tested a new combination of drugs (ribociclib plus topotecan and temozolomide) in children and young adults with relapsed or treatment-resistant neuroblastoma and other solid tumors. The goal was to see if the combination was safe and effective. The trial was terminated early, and only 12 participants were enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cohen Children's Medical Center of New York

    New Hyde Park, New York, 11040, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

  • Novartis Investigative Site

    Cologne, 50937, Germany

  • Novartis Investigative Site

    Milan, MI, 20133, Italy

  • Novartis Investigative Site

    Sutton, Surrey, SM2 5PT, United Kingdom

  • St Jude s Childrens Research Hospital

    Memphis, Tennessee, 38105-2794, United States

Conditions

Explore the condition pages connected to this study.